145 related articles for article (PubMed ID: 37636493)
1. Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.
Lehmann M; Hosa H; Bartl T; Tsibulak I; Polterauer S; Pötsch N; Seckl MJ; Marth C
Gynecol Oncol Rep; 2023 Oct; 49():101259. PubMed ID: 37636493
[TBL] [Abstract][Full Text] [Related]
2. A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab.
Niimi K; Yamamoto E; Oda Y; Nishiko Y; Shibata M; Nishino K; Kajiyama H
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):745-748. PubMed ID: 37679006
[TBL] [Abstract][Full Text] [Related]
3. Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN).
Mangili G; Sabetta G; Cioffi R; Rabaiotti E; Candotti G; Pella F; Candiani M; Bergamini A
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681761
[TBL] [Abstract][Full Text] [Related]
4. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients.
Soper JT; Spillman M; Sampson JH; Kirkpatrick JP; Wolf JK; Clarke-Pearson DL
Gynecol Oncol; 2007 Mar; 104(3):691-4. PubMed ID: 17137617
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary study of PD-1 inhibitor in the treatment of drug-resistant recurrent gestational trophoblastic neoplasia].
Cheng HY; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2020 Jun; 55(6):390-394. PubMed ID: 32842245
[No Abstract] [Full Text] [Related]
6. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
7. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral hemorrhage as initial presentation of gestational choriocarcinoma: a case report and literature review.
Huang CY; Chen CA; Hsieh CY; Cheng WF
Int J Gynecol Cancer; 2007; 17(5):1166-71. PubMed ID: 17425677
[TBL] [Abstract][Full Text] [Related]
9. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
[TBL] [Abstract][Full Text] [Related]
10. Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
Li L; Wan X; Feng F; Ren T; Yang J; Zhao J; Jiang F; Xiang Y
BMC Cancer; 2018 May; 18(1):585. PubMed ID: 29792175
[TBL] [Abstract][Full Text] [Related]
11. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
12. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA
Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721
[TBL] [Abstract][Full Text] [Related]
13. Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy.
Wong AJ; Finch L; Pearson JM; Pinto A; Huang M
Gynecol Oncol Rep; 2022 Apr; 40():100955. PubMed ID: 35300054
[TBL] [Abstract][Full Text] [Related]
14. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
15. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
Lurain JR; Nejad B
Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide.
Braga A; Mora P; de Melo AC; Nogueira-Rodrigues A; Amim-Junior J; Rezende-Filho J; Seckl MJ
World J Clin Oncol; 2019 Feb; 10(2):28-37. PubMed ID: 30815369
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.
Sato S; Yamamoto E; Niimi K; Ino K; Nishino K; Suzuki S; Kotani T; Kajiyama H; Kikkawa F
Int J Clin Oncol; 2020 Jan; 25(1):203-209. PubMed ID: 31520175
[TBL] [Abstract][Full Text] [Related]
18. Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature.
Kazemi NY; Langstraat C; John Weroha S
Gynecol Oncol Rep; 2022 Feb; 39():100923. PubMed ID: 35111894
[TBL] [Abstract][Full Text] [Related]
19. Treatment of low-risk gestational trophoblastic neoplasia.
Winter MC
Best Pract Res Clin Obstet Gynaecol; 2021 Jul; 74():67-80. PubMed ID: 33741258
[TBL] [Abstract][Full Text] [Related]
20. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
